Mexican drug regulator imposes Rs 28 lakh penalty on Dr Reddy's Labs

Written by Ruchika Sharma Published On 2024-09-26T16:26:35+05:30 | Updated On 26 Sept 2024 4:26 PM IST

Hyderabad: Dr Reddy's Labs has said in the BSE filing that the drug regulatory body of Mexico (Comisión Federal para la Protección contra Riesgos Sanitarios or Cofepris) has imposed a penalty of Rs 28 Lakh on the Company for deviation from prescribed guidelines for filing intimation of import of a reference standard for one of the active pharmaceutical ingredients (APIs).

The intimation was filed by the Company upon arrival of the reference standard in Mexico as opposed to three days in advance as required.

Read also: Dr. Reddy's Laboratories Gets CDSCO Panel Nod to Study FDC Telmisartan Plus Chlortalidone for Export purpose only

Established in 1984, Dr. Reddy’s Laboratories Ltd. is a global pharmaceutical company headquartered in Hyderabad, India. The Company offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr Reddy's Labs major markets include – USA, India, Russia & CIS countries, China, Brazil and Europe

dr reddys labsdr reddys labs news

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751